Buy your textbooks here

Free BCBA Text Books of Killexams.com | study guide | Braindumps | Study Guides | Textbook

Test prep for BCBA for New Course and Exam Simulator made up of practice questions - VCE - examcollection and braindumps are highly recommed before you sit in real test - study guide - Study Guides | Textbook

Pass4sure BCBA dumps | Killexams.com BCBA true questions | https://www.textbookw.com/


Killexams.com BCBA Dumps and true Questions

100% true Questions - Exam Pass Guarantee with towering Marks - Just Memorize the Answers



BCBA exam Dumps Source : Board Certification in trade Valuation(R) (BCBA)

Test Code : BCBA
Test designation : Board Certification in trade Valuation(R) (BCBA)
Vendor designation : Real-Estate
: 251 true Questions

Right location to find BCBA Latest dumps paper.
I exceeded the BCBA exam thanks to this bundle. The questions are accurate, and so are the subjects and pick a contemplate at courses. The format could subsist very convenient and permits you to examine in one-of-a-kind codecs - practising at the trying out engine, studying PDFs and printouts, so that you can exercise session the style and stability thats prerogative for you. I personally loved practising on the trying out engine. It completely simulates the exam, thats especially vital for BCBA exam, with everything their specific query sorts. So, its a bendy but answerable way to attain your BCBA certification. Ill subsist using killexams.com for my subsequent stage certification checks, too.


BCBA exam isn't any greater tough with these QAs.
The solutions are explained in short in simple language and nonetheless construct pretty an repercussion thats clean to understand and observe. I took the assist of killexams.com and exceeded my BCBA exam with a wholesome rating of sixty nine. way to killexams.com . I would really fancy to witness in favor of killexams.com for the practise of BCBA examination


it's miles unbelieveable, but BCBA today's dumps are availabe prerogative here.
Phrase of mouth is a very tenacious manner of advertising and advertising for a product. I say, whilst some thing is so suitable, why no longer accomplish a dinky towering fine publicity for it I would really fancy to unfold the word approximately this one in every of a kindhearted and definitely extremely obliging killexams.Com which helped me in appearing outstandingly well in my BCBA examination and exceeding everything expectations. I might bid that this killexams.Com is one of the maximum admirable on line education ventures i believe ever approach across and it merits a whole lot of recognition.


What is needed to examine for BCBA examination?
that is my first time that I took this provider. I feel very confident in BCBA but. I set aside together my BCBA the exercise of questions and answers with exam simulator softare via killexams.com team.


Dumps of BCBA exam are available now.
applicants expend months looking to rep themselves prepared for their BCBA assessments however for me it changed into everything just a days work. youll phenomenon how someone would believe the faculty to finish this kindhearted of super task in only a day let me inform you, everything I had to accomplish turned into badge in myself on this killexams.com and the whole thing changed into precise after that. My BCBA check seemed fancy a very simple challenge due to the fact i was so nicely prepared for it. I thank this web site for lending me a assisting hand.


discovered an amend source for true BCBA synchronous dumps.
I certainly asked it, honed for a week, then went in and surpassed the exam with 89% marks. that is the issue that the proper examination arrangement ought to subsist much fancy for each person! I got to subsist BCBA affirmed accomplice attributable to this web page. theyve an excellent accumulation of killexams.com and examination association property and this time their stuff is exactly as super. The inquiries are valid, and the examination simulator works best. No troubles identified. I suggested killexams.com Steadfast!!


What are requirements to pass BCBA examination in dinky attempt?
Killexams.Com substances cowl each component of BCBA , round which the BCBA exam is built. So if youre new to it, this is a need to. I needed to step up my expertise of BCBA qa has helped me loads. I exceeded the BCBA examination way to killexams.Com and had been recommending it to my friends and co-workers.


It changed into first revel in however remarkable experience!
I didnt plot to apply any intelligence dumps for my IT certification assessments, but being underneath strain of the problem of BCBA exam, I ordered this bundle. I was stimulated through the nice of those substances, theyre in fact worth the coins, and that i believe that theyll value greater, this is how notable they are! I didnt believe any hassle even astaking my exam thanks to Killexams. I really knew everything questions and answers! I got ninety seven% with just a few weeks examination education, except having some paintings enjoy, which modified into virtually beneficial, too. So sure, killexams.com is definitely properly and enormously endorsed.


in which am i able to find BCBA dumps questions?
I were given this percent and exceeded the BCBA exam with ninety seven% marks after 10 days. Im quite fulfilled via the conclude result. There may subsist extremely obliging stuff for associate stage confirmations, however regarding the expert level, I matter on that is the precept tenacious plot of action for high-quality stuff, particularly with the exam simulator that gives you a danger to exercise with the advent and suffer of a true examination. That is a definitely substantial brain dump, true observe manual. That is elusive for cutting aspect exams.


where am i able to find observe steer for exact knowledge of BCBA exam?
Id advise this query bank as a should must everything and sundry who is preparing for the BCBA exam. It became very profitable in getting an view as to what configuration of questions were coming and which regions to interest. The exercise check provided was furthermore brilliant in getting a suffer of what to await on examination day. As for the solutions keys supplied, it become of first rate assist in recollecting what I had learnt and the explanations provided believe been facile to understand and definately brought saturate to my concept on the difficulty.


Real-Estate Real-Estate Board Certification in

true property utility market set to develop based on forecasts | killexams.com true Questions and Pass4sure dumps

This document reviews precise estate utility in world market, exceptionally in North the us, Europe, China, Japan, Korea and Taiwan, specializes in precise producers in world market, with skill, production, price, income and market partake for each company, masking Intel

The record on precise estate utility market is an all-inclusive contemplate at of the latest scenario of the trade with the bottom 12 months being 2019 and its growth possibilities over 2019-2025. The file is a painstaking recreation to present a comprehensive overview of true property application market in accordance with boom alternatives and market shares.

This record offers an in-depth research about the yardstick condition of staunch property utility market and tasks an silhouette of its growth market. It furthermore gives the critical points of the market and throughout most essential world regions in detail.

number on fundamental and secondary analysis has been conducted with the aim to compile required statistics for completing this particular document. Sever industry based mostly analytical suggestions has been narrowed down for a stronger realizing of this market.

file: www.researchnreports.com/request_sample.personal home page?id=77337

companies Profiled in this record includes    Intel

    Qualcomm

    NXP Semiconductors

    Texas contraptions

    Cypress Semiconductor

    Mediatek

    Microchip technology

    Renesas Electronics

    Stmicroelectronics

    Huawei applied sciences

    Nvidia

    advanced Micro devices

    Samsung Electronics

The progress of more suitable products and multiplied affected person effects has resulted due to the competitive environment in the market.

The document covers true estate utility market from the bottom line, starting from its definition. Later, it segments the market on a lot of standards to supply a depth of knowing on the a number of product types and pricing structures and purposes.

each and every aspect is examined cautiously by factoring in income, earnings and market dimension so as to believe in intelligence the talents of boom and scope.

file: www.researchnreports.com/.Hypertext Preprocessor?id=77337

 

motive to access precise property software Market research file:

analysis of actual estate application market and its upcoming boom possibilities is been outlined with maximum precision. This contemplate at contains an elaborative abstract of market which additionally contains snapshots that offer depth of information of a lot of other segmentations.

through qualitative and quantitative evaluation of key components which are liable for boosting or hampering the market growth and the promising alternatives in market were give. primary and secondary research is been done in aspect which helps the readers believe a powerful realizing of the comprehensive market for the forecast duration.

desk of Contents

world actual property application Market analysis file

Chapter 1 staunch property application Market Overview   

Chapter 2 international financial believe an repercussion on on trade   

Chapter 3 international Market competitors by using manufacturers 

Chapter four international construction, salary (price) via location

Chapter 5 international deliver (construction), Consumption, Export, Import by using regions 

Chapter 6 world construction, profits (value), fee style by using class   

Chapter 7 world Market evaluation with the aid of application   

Chapter 8 Manufacturing can saturate evaluation   

Chapter 9 Industrial Chain, Sourcing approach and Downstream patrons   

Chapter 10 marketing approach evaluation, Distributors/traders 

Chapter 11 Market sequel factors analysis   

Chapter 12 global actual property application Market Forecast

record: www.researchnreports.com/.personal home page?identification=77337

This electronic mail address is being blanketed from spambots. You want JavaScript enabled to view it.


Morguard actual estate funding believe faith broadcasts CFO Transition | killexams.com true Questions and Pass4sure dumps

No outcomes discovered, try new keyword!MISSISSAUGA, ON, Nov. 12, 2018 /CNW/ - The Board of Trustees of the Morguard staunch estate funding believe (the "have confidence") (TSX: MRT.UN) these days announced that it has authorized a main monetary Officer ("C...

precise property : If I change my intellect about renting a spot, can they maintain my deposit? | killexams.com true Questions and Pass4sure dumps

Q: They were going to rent a home in a condo community. They stuffed out the application and left a $250 deposit. a number of days later, they were counseled that they had been accepted and vital to pay an extra $850 for the deposit. They went and left the assess but could not finalize the rent because the supervisor become no longer on the office. Over the weekend, they determined that they didn't are looking to appoint there and referred to as Monday to query for their money back. they are refusing. Can they maintain their funds? — Linda

A: No, doubtless not, or at least now not most of it. i am going to exercise this break to restate some tips that I can not loom to bid satisfactory: accomplish not signal anything unless and until you examine it and pick note what it says.

in case you aren't positive what it ability, accomplish not signal except you do. i am going to proceed out on a limb and matter on that your initial $250 “deposit” turned into an “software price,” which you agreed to pay somewhere within the pleasant print of the multi-web page utility. If here is correct, you believe got already spent those $250, and they are gone. you should review your reproduction of the kindhearted (at everything times rep a copy of every thing you signal!) and corroborate this. If it became a deposit and not a charge, subsist positive you subsist in a position to rep it returned.

The $850 assess goes to depend upon if and what you signed in case you dropped off the assess. in case you simply left it with the workplace and did not badge the lease documents, they'll need to recrudesce your cash. despite the fact, if you signed a lease, you may subsist accountable in your deposit and even some hire, depending on the phrases of the contract you signed.

You may additionally believe furthermore signed, both on the time of utility or for those who dropped off the 2nd assess, a “reservation” kindhearted that holds the unit for you until a lease is utterly signed. If here is the case, you'll should evaluation the terms of the reservation to peer when you are entitled to money back.

———

concerning the author

Gary M. Singer is a Florida counsel and board-licensed as an authority in actual property legislation by the Florida Bar. He practices actual property, company litigation and contract legislations from his office in rupture of day, Fla. he is the chairman of the true property component to the Broward County Bar association and is a co-host of the weekly radio panoply prison word and evaluation. He commonly consults on established staunch estate concerns and developments in Florida with various groups throughout the nation. route him questions on-line at www.sunsentinel.com/askpro or supervene him on Twitter @GarySingerLaw.

Copyright 2018 Tribune content material agency.




Killexams.com BCBA Dumps and true Questions

100% true Questions - Exam Pass Guarantee with towering Marks - Just Memorize the Answers



BCBA exam Dumps Source : Board Certification in trade Valuation(R) (BCBA)

Test Code : BCBA
Test designation : Board Certification in trade Valuation(R) (BCBA)
Vendor designation : Real-Estate
: 251 true Questions

Right location to find BCBA Latest dumps paper.
I exceeded the BCBA exam thanks to this bundle. The questions are accurate, and so are the subjects and pick a contemplate at courses. The format could subsist very convenient and permits you to examine in one-of-a-kind codecs - practising at the trying out engine, studying PDFs and printouts, so that you can exercise session the style and stability thats prerogative for you. I personally loved practising on the trying out engine. It completely simulates the exam, thats especially vital for BCBA exam, with everything their specific query sorts. So, its a bendy but answerable way to attain your BCBA certification. Ill subsist using killexams.com for my subsequent stage certification checks, too.


BCBA exam isn't any greater tough with these QAs.
The solutions are explained in short in simple language and nonetheless construct pretty an repercussion thats clean to understand and observe. I took the assist of killexams.com and exceeded my BCBA exam with a wholesome rating of sixty nine. way to killexams.com . I would really fancy to witness in favor of killexams.com for the practise of BCBA examination


it's miles unbelieveable, but BCBA today's dumps are availabe prerogative here.
Phrase of mouth is a very tenacious manner of advertising and advertising for a product. I say, whilst some thing is so suitable, why no longer accomplish a dinky towering fine publicity for it I would really fancy to unfold the word approximately this one in every of a kindhearted and definitely extremely obliging killexams.Com which helped me in appearing outstandingly well in my BCBA examination and exceeding everything expectations. I might bid that this killexams.Com is one of the maximum admirable on line education ventures i believe ever approach across and it merits a whole lot of recognition.


What is needed to examine for BCBA examination?
that is my first time that I took this provider. I feel very confident in BCBA but. I set aside together my BCBA the exercise of questions and answers with exam simulator softare via killexams.com team.


Dumps of BCBA exam are available now.
applicants expend months looking to rep themselves prepared for their BCBA assessments however for me it changed into everything just a days work. youll phenomenon how someone would believe the faculty to finish this kindhearted of super task in only a day let me inform you, everything I had to accomplish turned into badge in myself on this killexams.com and the whole thing changed into precise after that. My BCBA check seemed fancy a very simple challenge due to the fact i was so nicely prepared for it. I thank this web site for lending me a assisting hand.


discovered an amend source for true BCBA synchronous dumps.
I certainly asked it, honed for a week, then went in and surpassed the exam with 89% marks. that is the issue that the proper examination arrangement ought to subsist much fancy for each person! I got to subsist BCBA affirmed accomplice attributable to this web page. theyve an excellent accumulation of killexams.com and examination association property and this time their stuff is exactly as super. The inquiries are valid, and the examination simulator works best. No troubles identified. I suggested killexams.com Steadfast!!


What are requirements to pass BCBA examination in dinky attempt?
Killexams.Com substances cowl each component of BCBA , round which the BCBA exam is built. So if youre new to it, this is a need to. I needed to step up my expertise of BCBA qa has helped me loads. I exceeded the BCBA examination way to killexams.Com and had been recommending it to my friends and co-workers.


It changed into first revel in however remarkable experience!
I didnt plot to apply any intelligence dumps for my IT certification assessments, but being underneath strain of the problem of BCBA exam, I ordered this bundle. I was stimulated through the nice of those substances, theyre in fact worth the coins, and that i believe that theyll value greater, this is how notable they are! I didnt believe any hassle even astaking my exam thanks to Killexams. I really knew everything questions and answers! I got ninety seven% with just a few weeks examination education, except having some paintings enjoy, which modified into virtually beneficial, too. So sure, killexams.com is definitely properly and enormously endorsed.


in which am i able to find BCBA dumps questions?
I were given this percent and exceeded the BCBA exam with ninety seven% marks after 10 days. Im quite fulfilled via the conclude result. There may subsist extremely obliging stuff for associate stage confirmations, however regarding the expert level, I matter on that is the precept tenacious plot of action for high-quality stuff, particularly with the exam simulator that gives you a danger to exercise with the advent and suffer of a true examination. That is a definitely substantial brain dump, true observe manual. That is elusive for cutting aspect exams.


where am i able to find observe steer for exact knowledge of BCBA exam?
Id advise this query bank as a should must everything and sundry who is preparing for the BCBA exam. It became very profitable in getting an view as to what configuration of questions were coming and which regions to interest. The exercise check provided was furthermore brilliant in getting a suffer of what to await on examination day. As for the solutions keys supplied, it become of first rate assist in recollecting what I had learnt and the explanations provided believe been facile to understand and definately brought saturate to my concept on the difficulty.


Unquestionably it is hard assignment to pick dependable certification questions/answers assets regarding review, reputation and validity since individuals rep sham because of picking incorrectly benefit. Killexams.com ensure to serve its customers best to its assets concerning exam dumps update and validity. The vast majority of other's sham report dissension customers approach to us for the brain dumps and pass their exams joyfully and effortlessly. They never trade off on their review, reputation and character on the grounds that killexams review, killexams reputation and killexams customer certainty is imperative to us. Uniquely they deal with killexams.com review, killexams.com reputation, killexams.com sham report objection, killexams.com trust, killexams.com validity, killexams.com report and killexams.com scam. On the off casual that you remark any wrong report posted by their rivals with the designation killexams sham report grievance web, killexams.com sham report, killexams.com scam, killexams.com protest or something fancy this, simply bethink there are constantly dreadful individuals harming reputation of obliging administrations because of their advantages. There are a huge number of fulfilled clients that pass their exams utilizing killexams.com brain dumps, killexams PDF questions, killexams hone questions, killexams exam simulator. Visit Killexams.com, their specimen questions and test brain dumps, their exam simulator and you will realize that killexams.com is the best brain dumps site.


Vk Profile
Vk Details
Tumbler
linkedin
Killexams Reddit
digg
Slashdot
Facebook
Twitter
dzone
Instagram
Google Album
Google About me
Youtube



310-100 true questions | 3101 braindumps | 000-080 exam prep | 000-997 exercise Test | 1Z0-506 sample test | 000-176 questions and answers | 1Y0-401 study guide | HP0-J48 true questions | C9530-001 exercise exam | BCP-221 free pdf | HP2-E41 dump | 000-561 exam prep | 000-N04 true questions | C2180-607 mock exam | C2020-642 free pdf | HP0-500 brain dumps | EPPP exercise questions | 650-621 brain dumps | 000-537 cram | M9510-747 exercise test |


BCBA exam questions | BCBA free pdf | BCBA pdf download | BCBA test questions | BCBA real questions | BCBA practice questions

Real BCBA questions that appeared in test today
We believe Tested and Approved BCBA Exams. killexams.com gives the most specific and most recent IT exam materials which nearly comprise everything exam topics. With the database of their BCBA exam materials, you accomplish not believe to squander your break on perusing time consuming reference books and surely need to singe thru 10-20 hours to ace their BCBA true questions and answers.

Are you searching for Real-Estate BCBA Dumps containing true exam Questions and Answers for the Board Certification in trade Valuation(R) (BCBA) test prep? they offer most updated and character supply of BCBA Dumps that's http://killexams.com/pass4sure/exam-detail/BCBA. they believe got compiled an information of BCBA Dumps questions from actual tests so as to allow you to prepare and pass BCBA exam on the first attempt. killexams.com Discount Coupons and Promo Codes are as under; WC2017 : 60% Discount Coupon for everything exams on website PROF17 : 10% Discount Coupon for Orders larger than $69 DEAL17 : 15% Discount Coupon for Orders larger than $99 SEPSPECIAL : 10% Special Discount Coupon for everything Orders You ought to rep the recently updated Real-Estate BCBA Braindumps with the amend answers, that are ready via killexams.com specialists, helping the candidates to understand and suffer regarding their BCBA exam path, you will not realize BCBA exam of such character within the marketplace. Their Real-Estate BCBA brain Dumps are given to candidates at acting 100% of their test. Their Real-Estate BCBA exam dumps are working noteworthy within the test centers, providing you with an break to location along in your BCBA exam.

At killexams.com, they give explored Real-Estate BCBA tutoring assets which can subsist the best to pass BCBA test, and to rep authorized by Real-Estate. It is an incredible inclination to quicken your vocation as an expert in the Information Technology endeavor. They are content with their notoriety of supporting individuals pass the BCBA exam of their first endeavors. Their prosperity costs in the previous years had been really astonishing, on account of their jubilant customers presently ready to advocate their profession inside the rapid path. killexams.com is the essential determination among IT experts, particularly the individuals trying to inch up the progressive system goes quicker in their divide companies. Real-Estate is the undertaking pioneer in records age, and getting ensured by them is an ensured approach to win with IT vocations. They enable you to accomplish precisely that with their unnecessary wonderful Real-Estate BCBA tutoring materials.

Real-Estate BCBA is inescapable everything around the globe, and the trade undertaking and programming arrangements given by utilizing them are grasped by way for about the greater Part of the associations. They believe helped in driving heaps of organizations on the beyond any doubt shot course of pass. Extensive data of Real-Estate items are taken into preparation a totally imperative capability, and the specialists certified by way for them are very esteemed in everything associations.

We offer genuine BCBA pdf exam inquiries and answers braindumps in positions. Download PDF and exercise Tests. Pass Real-Estate BCBA digital bespeak Exam rapidly and effortlessly. The BCBA braindumps PDF compose is to subsist had for perusing and printing. You can print more noteworthy and exercise typically. Their pass rate is towering to 98.9% and the similarity percent between their BCBA syllabus study manual and genuine exam is 90% construct absolutely Considering their seven-yr instructing knowledge. accomplish you need accomplishments inside the BCBA exam in only one attempt? I am now dissecting for the Real-Estate BCBA genuine exam.

As the only thing in any way essential here is passing the BCBA - Board Certification in trade Valuation(R) (BCBA) exam. As everything which you require is a towering score of Real-Estate BCBA exam. The best one angle you believe to accomplish is downloading braindumps of BCBA exam courses now. They will never again will give you a casual to down with their cash back guarantee. The specialists moreover protect beat with the greatest forward exam so you can give the vast majority of updated materials. Three months free rep passage to as an approach to them through the date of purchase. Each hopeful may likewise manage the cost of the BCBA exam dumps through killexams.com at a low cost. Regularly there might subsist a diminish for everything individuals all.

Within the sight of the staunch exam purport of the brain dumps at killexams.com you may effortlessly grow your specialty. For the IT experts, it's far critical to adjust their abilities answerable with their calling necessity. They construct it smooth for their clients to pick accreditation exam with the assistance of killexams.com demonstrated and honest to goodness exam material. For a splendid future in its realm, their intelligence dumps are the noteworthy decision.

killexams.com Huge Discount Coupons and Promo Codes are as under;
WC2017: 60% Discount Coupon for everything exams on website
PROF17: 10% Discount Coupon for Orders greater than $69
DEAL17: 15% Discount Coupon for Orders greater than $99
OCTSPECIAL: 10% Special Discount Coupon for everything Orders


A best dumps composing is an absolutely imperative component that makes it simple a decent way to pick Real-Estate certifications. subsist that as it may, BCBA braindumps PDF gives accommodation for hopefuls. The IT certification is a significant troublesome task on the off casual that one does now not find prerogative direction inside the ilk of certifiable helpful asset material. Along these lines, we've genuine and state-of-the-art content material for the instruction of accreditation exam.

BCBA Practice Test | BCBA examcollection | BCBA VCE | BCBA study guide | BCBA practice exam | BCBA cram


Killexams CHA cram | Killexams 1Y0-327 braindumps | Killexams 920-352 questions and answers | Killexams C2180-319 exercise test | Killexams 000-234 study guide | Killexams JN0-102 true questions | Killexams ISEB-BA1 braindumps | Killexams SCNS-EN cheat sheets | Killexams 6007 free pdf | Killexams 000-M86 test prep | Killexams A2180-607 test prep | Killexams 2U00210A examcollection | Killexams HP2-Z22 exercise test | Killexams 920-249 dumps | Killexams 1Z0-242 brain dumps | Killexams 000-545 dumps questions | Killexams 250-311 exercise questions | Killexams 1D0-441 exam questions | Killexams COG-185 mock exam | Killexams 642-278 free pdf download |


killexams.com huge List of Exam Study Guides

View Complete list of Killexams.com Brain dumps


Killexams 1K0-001 study guide | Killexams 3C00120A brain dumps | Killexams HP2-H21 exam questions | Killexams TB0-107 exercise questions | Killexams E20-330 true questions | Killexams UM0-300 free pdf | Killexams NS0-310 brain dumps | Killexams 650-042 exercise questions | Killexams MB2-184 exercise Test | Killexams NSE6 exercise test | Killexams 210-065 exercise test | Killexams LX0-103 exercise exam | Killexams C2010-653 cram | Killexams 1Z0-971 pdf download | Killexams 9L0-066 examcollection | Killexams C9520-423 dumps questions | Killexams MB7-255 questions and answers | Killexams HP0-M46 test questions | Killexams C2140-842 questions answers | Killexams Property-and-Casualty braindumps |


Board Certification in trade Valuation(R) (BCBA)

Pass 4 positive BCBA dumps | Killexams.com BCBA true questions | https://www.textbookw.com/

Business bulletins: Lubbockites earn promotions and awards | killexams.com true questions and Pass4sure dumps

PSC promotes several in Lubbock

Parkhill, Smith & Cooper has recently promoted several design professionals from its Lubbock office.

Brandon Hartley, AIA, has been promoted to associate. He is a member of the healthcare sector and a BIM coordinator. He has been heavily involved with developing standards to assist achieve a towering flush of materiel integration and assist with facilities management through BIM software. Hartley has been with PSC for 10 years.

Michael Krusing, PE, has been promoted to associate. As a team leader in the aviation sector, he pulls from his design and construction oversight expertise to give their clients the same flush of service that helped win the 2015 and 2017 TxDOT Aviation’s Most Improved common Aviation Airport of the Year. Krusing has designed multiple projects for TxDOT Aviation and new Mexico Department of Transportation. Krusing has been with PSC for nearly 11 years.

Todd Stiggins, PE, has been promoted to associate. He is a project manager for municipal solid waste in PSC’s environmental sector. His suffer includes engineering design and construction services for over 150 acres of MSW landfill liner, final cover and capital improvement projects in Texas and Oklahoma, including managing project scopes, schedules and budgets in excess of $50 million. Todd has been with PSC for two years and has 15 years of experience. 

^

Galley joins local law firm

Jonathan Galley has joined the law solid of Craig, Terrill, Hale & Grantham.

The law solid specializes in civil legal matters.

Galley earned his juris doctorate from the University of Tulsa College of Law and has been licensed for seven years.

Bass named to super counsel list

R. Byrn “Byrnie” Bass, Jr. was selected for the 2018 Texas Super counsel List.

Bass was recognized for his toil in trade bankruptcies. This is the thirteenth time he has been named to the list.

Bass is past chairman of the bankruptcy law section of the condition Bar of Texas, past president of the West Texas Bankruptcy Bar Association and furthermore past president of the Lubbock County Bar Association. In 2013 he was the recipient of the condition Bar Bankruptcy Law Section’s Pro Bono Service Award. He graduated from Baylor University in 1969 and received his Law Degree from the University of Texas School of Law in 1972.

Bass furthermore chaired the 2014 Lubbock belt United way crusade and currently serves on the board of directors of the Lubbock Chamber of Commerce.

^

Mears earns national recognition

Nick Mears has been nominated by the National Association of Certified Valuators and Analysts (NACVA) to the 2018 40 Under Forty program.

This program recognizes 40 individuals across the U.S. who are under 40 years brokendown and exemplify the brightest emerging leaders in the trade valuation profession.

Mears is a managing member and founder of Lubbock-based Caprock trade Consulting.

"I am honored to subsist Part of this prestigious program and thank you NACVA for your consideration as one of the top emerging leaders in the trade valuation community across the country," he said.

Submit trade word to sself-walbrick@lubbockonline.com. Announcements are due Thursday at noon for Sunday publication.


Ionis Pharmaceuticals, Inc. (IONS) Q3 2018 Earnings Conference convene Transcript | killexams.com true questions and Pass4sure dumps

Logo of jester cap with thought bubble.© The Motley Fool Logo of jester cap with thought bubble.

Ionis Pharmaceuticals, Inc.  (NASDAQ: IONS)

Q3 2018 Earnings Conference Call

Nov. 06, 2018, 11:30 a.m. ET

Ionis Pharmaceuticals Inc

Contents:
  • Prepared Remarks
  • Questions and Answers
  • Call Participants
  • Prepared Remarks:

    Operator

    Good morning, and welcome to the Ionis Pharmaceuticals Third Quarter 2018 financial Results Conference Call. As a reminder, this convene is being recorded.

    At this time, I would fancy to circle the convene over to Wade Walke, Vice President, Investor Relations, to lead off the call. gladden begin.

    Wade Walke -- Vice President, Investor Relations

    Thank you, Cole. Before they begin, I cheer everyone to proceed to the Investor section of the Ionis website to find their press release and the related financial tables, including the reconciliation of the GAAP to pro forma financial measures that they will discuss today. They believe pro forma financial results better represent the economics of their trade and how they manage their business. They believe furthermore posted slides on their website that accompany their discussion today.

    With me on the convene are today are Stan Crooke, Chairman of the Board and Chief Executive Officer; Beth Hougen, Chief financial Officer; Damien McDevitt, Chief trade Officer; and Brett Monia, Chief Operating Officer.

    I would fancy to draw your attention to glide three which contains their forward-looking language statement which we'll subsist making today, forward-looking language statements which are based on their current expectations and beliefs. These statements are matter to unavoidable risks and uncertainties, and their actual results may vary materially. I cheer you to consult the risk factors discussed in their SEC filings for additional details.

    And with that, I'll circle the convene over to Stan.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    Thanks, Wade, and obliging morning, everyone. Thanks for joining us. In the third quarter, they achieved a number of essential milestones, and in the aggregate that results in continued financial energy for the company. We're on track for their third consecutive year of pro forma operating income, and we're doing this while launching TEGSEDI and preparing to launch WAYLIVRA.

    Our solid financial performance results from more sources of revenue including growing SPINRAZA revenue on top of their substantial base of R&D revenue from numerous successful partnerships. With the TEGSEDI launch under way, they contemplate forward to adding commercial revenue from this drug and potentially WAYLIVRA. They await SPINRAZA sales to continue to grow globally, given the positive new data Biogen reported from the nature study in pre-symptomatic infants.

    We furthermore await to remark continued growth in key patient segments such as the adult patients in the US which construct up 60% of the SMA population, with only a fraction of those patients now being treated. Positive repercussion of SPINRAZA has now been recognized with several Prix Galien awards around the world, and was furthermore recently recognized again by the scientific community with the awarding of the breakthrough prize in life sciences to candid Bennett, their SVP of Research and Head of Neurological Disease Franchise. candid shared this honor with Dr. Adrian Krainer of icy Spring Harbor Laboratory.

    The TEGSEDI launch is now under way in multiple countries, and they and their affiliate Akcea are encouraged by the continuing enthusiasm they are seeing from the amyloidosis community for this drug with tenacious team, the necessary infrastructure and global strategy in place, they are confident in Akcea's faculty to successfully launch TEGSEDI.

    With WAYLIVRA, they and Akcea are in dynamic discussions with EMA, and they continue their conversations for path forward with the FDA. everything of these review processes are progressing.

    Our EAP program is going well, and they continue to toil to bring everything the patients with FCS, the first-ever treatment of this ultra-rare, debilitating and potentially deadly disease. In the aspect 2 study of AKCEA-APO(a)-LRx, the drug demonstrated substantial dose-dependent reductions in a Lp(a) in patients with established cardiovascular disease and elevated Lp(a). They furthermore observed the benign safety and tolerability profile. We're very encouraged by the drug's performance using convenient low-volume monthly doses.

    We and Akcea, along with their confederate Novartis, now believe what they need to select a dose and foster the drug into a large cardiovascular outcome study to demonstrate the cardiovascular benefits of lowering Lp(a), genetically validated driver cardiovascular disease affecting millions of patients worldwide. aspect 2 study of APO(a)-LRx is the largest and the longest study of a LICA drug today, with nearly 300 patients dosed up to 12 months.

    Robust target reduction and benign safety and tolerability profile observed in this study adds to their self-possession in the potential of LICA drugs to treat a broad compass of diseases with convenient dosing regimens.

    Roche expects to initiate the aspect 3 program for IONIS-HTTRx in patients with Huntington disease before the year-end, including a pivotal study and a natural history study. pile on their successful relationship with Roche, they entered a new collaboration to the progress of Ionis factor B LRx. For the treatment of patients with a broad compass of complement-mediated diseases genesis with geographic atrophy, the advanced stage of parch age-related macular degeneration.

    We believe Roche is the prerogative confederate to maximize the potential for success of this program, and the substantial flush of participation they retain in the drug's commercial success is another instance of the tenacious value of their antisense platform.

    Beyond these essential highlights, we've had numerous other pipeline achievements which not only contribute to their significant financial strength, but more importantly panoply that essential new drugs they are advancing closure to patients who desperately need it. Their focus remains on delivering innovative new medicines to patients in need, while positioning the company for continued growth.

    I'll now circle the convene over to Beth.

    Elizabeth L. Hougen -- Senior Vice President, Finance & Chief financial Officer

    Thank you, Stan. obliging morning, everyone. They ended the first nine months of 2018 with operating income of $25 million and net income of $51 million, both on a pro forma basis. Their tenacious financial results were driven by double-digit revenue growth compared to the same era in 2017, a nearly threefold extend in commercial revenue from SPINRAZA royalties compared to the first nine months of 2017 together with a substantial base of R&D revenue were key factors contributing to their financial performance this year. Additionally, they ended the third quarter with approximately $2 billion in cash.

    With TEGSEDI now launched in multiple countries, and a catalyst-rich next six months, they are positioned for continued financial success. They project their fourth quarter results will subsist driven by growth in commercial revenue from SPINRAZA royalties as global sales increase. eventual quarter, they moved into the highest royalty tier which means they earn a greater partake of each dollar of SPINRAZA sales. In addition, they await TEGSEDI product sales to contribute to their commercial revenue growth in the fourth quarter.

    We furthermore project their fourth quarter R&D revenue to extend due to the amortization of the $75 million upfront payment from their new collaboration with Roche for their FB program. And already this quarter they believe earned two milestone payments from AstraZeneca, totaling nearly $30 million for advancing two different programs.

    We are on track to easily meet their guidance of pro forma operating income even while investing in the launch of TEGSEDI and preparing to launch WAYLIVRA. They are projecting to conclude the year with more than $1.8 billion in cash making us cash accretive for six out of the eventual seven years. They plot to exercise their cash to continue to foster and expand their pipeline including growing their pipeline of Ionis-owned drugs.

    Worldwide SPINRAZA revenues grew to $468 million driven by quarter-over-quarter and year-over-year revenue growth in the US and even greater revenue growth outside the US. Notably, year-to-date SPINRAZA global revenues surpassed $1 billion in the third quarter. The number of patients being treated with SPINRAZA increased by approximately 20% from the second quarter of 2018 and now nearly 6,000 patients are on SPINRAZA including in the EAP and clinical studies.

    In the US, more than 50% of new start forms in the third quarter were for adult patients, driving a greater than 20% extend in a number of US adult patients on SPINRAZA compared to the second quarter of 2018. Adult patients represent the largest SMA patients segment accounting for approximately 60% of the prevalent SMA patient population. However, only about 15% of these patients are receiving SPINRAZA today, representing a significant break for growth.

    Revenue growth outside the US was meaningful as the pace of reimbursement increased particularly in Europe, Asia Pacific and Latin America. They await revenue growth outside the US to continue in the fourth quarter of 2018 as the number of patients on treatment increases. That growth combined with stability in US SPINRAZA revenue in the fourth quarter compared to the third quarter of this year should result in increased royalty revenues from SPINRAZA which are nearly everything profit.

    R&D revenue for numerous drugs and numerous successful collaborations continues to subsist a significant component of their total revenue. So far this year, they believe earned more than $225 million in R&D revenue, which does not include the nearly $30 million in milestone payments we've earned so far in the fourth quarter. R&D revenue is a significant and sustainable source of revenue for us, which is why they include this source of revenue in their valuation model.

    As I discussed eventual quarter, their R&D revenue consists of four key components: amortization of upfront payments; milestone payments, which represents progress in their existing partnerships; license fees which represents new transactions and partner's advancing existing program and services they provide to their partners.

    Through the conclude of September, they had recognized $92 million of revenue from amortization and one significant component of this is in the third quarter with $14 million for the first plenary quarter of amortization for their new Biogen collaboration. They recognized $45 million in the first nine months of this year in milestone payments. Two significant milestone payments in the third quarter were $10 million from AstraZeneca when they initiated a aspect 1 study for the first drug in their cardiometabolic collaboration, and $10 million from Biogen when they initiated a aspect 1/2 clinical study evaluating their second drug to treat patients with ALS.

    We earned $64 million in R&D revenue during the first nine months of this year from license fees, primarily from AstraZeneca earlier in the year. This does not include the $12 million license fee they earned from the new collaboration with PTC to commercialize TEGSEDI and WAYLIVRA in Latin America, which they include in their commercial revenue. Finally, they earned $25 million from services they provided to their partners, primarily for manufacturing commercial and clinical supplies for them.

    Looking ahead, they await their R&D revenue to grow based on three factors: an extend in the number of partnerships, an extend in partnered program and larger payments as partnered programs advance.

    Let me give you some examples. First, their R&D revenue increases as the number of collaborations they believe increases. They recently entered into a second collaboration with Roche. Under this collaboration, they received a $75 million upfront payment. Together with Roche, they will subsist conducting a aspect 2 study in patients with geographic atrophy. Therefore, they will subsist amortizing the upfront payment over the course of the study genesis in the fourth quarter. They currently believe 13 collaborations with large pharmaceutical companies, a number that has more than doubled over the eventual six years.

    Second, they are progressing more and more programs under their successful collaboration. For each program they advance, they are eligible to earn milestone payments and license fees. They currently believe 22 partnered programs, a number that has nearly tripled since 2012. In 2012, they earned $51 million of revenue related to license fees and milestone payments. That's compared to over $135 million in license fees and milestone payments they believe earned so far this year.

    Third as their partnered programs advance, the dollar amount they earn for milestone payments and license fees increases, reflecting the extend in value of the advancing program. For example, when they initiated the aspect 1/2 study in Huntington's patients, they received a $22 million milestone payment from Roche to assist fund their cost to conduct the study. When Roche doses the first patient in the pivotal study, they will earn a $35 million milestone payment. Importantly, the $35 million will subsist everything profit to us since Roche will subsist conducting the study.

    In summary, they are sustainably profitable and cash accretive with a manageable expense structure. Their growing commercial revenues together with their substantial base of R&D revenue, positions us to finish 2018 in a tenacious financial position and sets us up for growth in 2019.

    With that, I'll circle the convene over to Damien to provide a commercial update.

    Damien McDevitt -- Chief trade Officer

    Great. Thank you, Beth. obliging morning, everyone. While it is early days in the TEGSEDI launch, they are pleased with the progress the Akcea team is making to rep TEGSEDI to the patients in need in the US, EU and Canada. While they are not providing sales guidance today, they and Akcea will reserve you updated on how the launch is going.

    TEGSEDI was recently approved in the US with a broad label for treatment of polyneuropathy of hATTR amyloidosis in adults, regardless of stage of disease. Akcea's patient advocate program has launched and is enrolling patients.

    AKCEA CONNECT was built to advocate patients through every step of their treatment journey, dedicated nurse case managers steer patients in establishing their monitoring routine as Part of the REMS program, assist navigate insurance coverage options, provide home injection training and more. And together with Akcea's lab service confederate Quest, patients believe the option for at-home services.

    Akcea's US field team is making obliging progress in connecting with treating physicians and they are pleased that the first prescriptions believe been received. In addition, the TEGSEDI market access team is well along with their efforts to confederate with payors. Importantly, the team is working with those payors who cover the majority of lives in the US to develop the strategy that best fits the goals and the patient population they serve while ensuring that financial barriers did not negatively repercussion patients in need.

    Akcea's specialty pharmacy Accredo has experienced in supporting this unique need of rare disease communities helping to simplify access to therapy. Today, Accredo has been certified into the REMS program and is ready to assist patients. Accredo has a team of specialty clinicians, pharmacists, and over 600 field-based nurses located throughout the US, who will augment the Akcea connect team of nurse case managers to provide advocate and address the needs of the hATTR community.

    In Germany, patients are now receiving TEGSEDI in the commercial setting. Akcea's goal is to ensure that patients who need TEGSEDI believe access to this. To accomplish this goal, Akcea is working to construct TEGSEDI available to patients across numerous countries in the EU as quickly as possible. Additionally, Akcea Connect is rolling out in the EU to provide the optimal flush of advocate for patients in each country.

    In Canada, Akcea Connect is in location and they contemplate forward to delivering the first drug to treat polyneuropathy caused by hATTR amyloidosis to these patients.

    Given TEGSEDI's robust efficacy and simple self-administration, they believe TEGSEDI will subsist the treatment of preference for people with hATTR and their physicians. Beyond the US, EU and Canada, they and Akcea contemplate forward to PTC Therapeutics piteous TEGSEDI forward in Latin America. They are furthermore looking to expand beyond these initial regions as Part of their strategy to enable global access to TEGSEDI.

    This weekend, at the International Society for Pharmacoeconomics and Outcomes Research meeting, Akcea is presenting more detailed analysis from the neuro TTR study demonstrating TEGSEDI's positive repercussion on patient's character of life. These analyses contemplate at TEGSEDI's sequel on patient's faculty to complete day-to-day activities, as well as positive changes in physical and mental health.

    Now turning to WAYLIVRA. In the EU, their review process is ongoing. In the US and Canada, they plot to toil with regulators to corroborate a path forward. As Akcea continues to toil to bring the first ever treatment to patients with FCS, the EAP program is ongoing and Akcea is prepared to launch in the EU as quickly as viable assuming approval. In addition, Akcea is making progress with patient identification with a focus on diagnosis which provides advocate for their assay of 3,000 to 5,000 FCS patients worldwide.

    Now, over to Brett, to review key highlights from their pipeline.

    Brett P. Monia -- Chief Operating Officer and Senior Vice President, Translational Medicine

    Thanks, Damien. So, they achieved several additional successes since their second quarter update that I'll now review briefly, and they contemplate forward to providing a detailed update at their Investor Day next month. Biogen recently provided an exciting update from the foster study in pre-symptomatic infants with SMA. As of May 2018, everything patients in this study were alive without the need for permanent ventilation, everything were sitting independently, and nearly everything were able to walk. And importantly, every participant in this study has continued to construct progress and achieved milestones more consistent with established development.

    These long-term data provide further evidence that early diagnosis of SMA in treatment with SPINRAZA can fundamentally alter the course of this disease for pre-symptomatic infants and adds to the body of evidence supporting SPINRAZA as it would subsist yardstick of supervision for everything patients with SMA.

    Shifting gears a bit, in the aspect 2 study of AKCEA-APO(a)-LRx, patients with established cardiovascular disease in elevated Lp(a) levels achieved dose-dependent reductions in Lp(a) with most patients in the dynamic group attaining levels below the established threshold of risk for cardiovascular disease. Additionally, APO(a)-LRx demonstrated a benign safety and tolerability profile consistent with their other LICA drugs. As is well documented, elevated Lp(a) levels is a driver of cardiovascular disease that affects millions of people worldwide. It cannot subsist controlled with lifestyle modifications such as diet or exercise, and there are no approved therapies that specifically target and reduce Lp(a) levels.

    The Ionis and Akcea team with their confederate Novartis are now preparing for an end-of-Phase 2 meeting with the FDA followed by the potential initiation of a large cardiovascular outcome study which will subsist designed to demonstrate the cardiovascular benefits of lowering Lp(a) levels in patients with established cardiovascular disease. Novartis, of course, is highly experienced in conducting large CV outcome studies, and they believe been actively preparing to initiate the study once they exercise their option.

    And importantly with royalties up to the low 20% range, they retain significant value in the commercial success of the drug. They contemplate forward to presenting additional data from the aspect 2 study this Saturday at AHA and at their Investor Day next month.

    Shifting attention, their confederate AstraZeneca recently reported positive aspect 2 data for danvatirsen, their STAT3 inhibitor at this year's ESMO conference. In combination with durvalumab, AstraZeneca's PD-L1 blocking antibody in recurrent metastatic head and neck cancer treatment resulted in 7% of patients achieving a complete tumor response and 23% achieving either a partial or a complete tumor response. This response rate is estimated to subsist double that of durvalumab alone, based on previous studies in this difficult to treat patient population.

    And their partnership with Roche continues to proceed well also. Roche announced the study design for the IONIS-HTTRx pivotal program which they plot to initiate before the conclude of the year. Working closely with regulators, Roche has designed a highly innovative pivotal study to generate a robust data set. They rep this essential medicine to people with Huntington's disease as rapidly as possible.

    The program will include two studies with patients genesis to enroll by early 2019. The first study is a aspect 3 study which will subsist the world's first to measure the sequel of a drug that will directly reduce the amount of the protein that causes Huntington's disease in patients. This three-year study will evaluate long-term safety and efficacy in up to 660 symptomatic Huntington's disease patients around the globe.

    The second study is a 15-month natural history study in up to 100 symptomatic patients designed to further their understanding of the correlation between changes in new huntingtin protein and clinical measures.

    As a reminder, IONIS-HTTRx is the first and only drug to demonstrate a substantial lowering of the new huntingtin protein (inaudible) in clinical capitalize in patients with Huntington's disease which together advocate the drug's potential to slack or perhaps half disease progression.

    As Stan mentioned, we've recently built upon their successful relationship with Roche with a new collaboration for the progress and commercialization of Ionis FPL or actually for the treatment of people with a broad compass of complement-mediated diseases genesis with geographic atrophy, the advanced stage of parch AMD.

    As a reminder, for each product in their pipeline, they remark the commercialization strategy that maximizes the drug's commercial success while optimizing their participation in that success. When partnered with IONIS-FB-LRx requesting for progress of drugs for renal disease and particularly geographic atrophy is intricate and requires specialized experience.

    Roche has a substantial progress infrastructure and suffer in developing and commercializing medicines for renal diseases. Furthermore, Roche is prepared to pursue additional complement mediated disease indications well-suited for IONIS-FB-LRx. Importantly, with royalties of up to 20% they participate substantially in the commercial success of this drug. And in the coming months, they contemplate forward to showing more of the data they believe generated from their LICA programs, their other LICA programs, in clinical studies, and publishing the plenary integrated safety database for these LICA drugs which are performing exceptionally well.

    In clinical studies, their LICA drugs had demonstrated increases in potency of 30-fold or greater enabling low volume and less frequent dosing. We've furthermore reserved obliging safety and tolerability potent target production. These results are consistent with those observed in the aspect 2 study of their APO(a)-LRx drug in nearly 300 patients treated for up to a year. Finally, they believe had many additional achievements since their second quarter update. They completed their enrollment of a aspect 2b study of IONIS-FactorXIRx in patients with end-stage renal disease on dialysis and initiated a aspect 1 study of the LICA version IONIS-FactorXI-LRx both with data expected in the second half of 2019.

    AstraZeneca initiated a aspect 1 study of their first generation 2.5 LICA drug to enter the clinic IONIS-AZ4-2.5-LRx, which is one of the three drugs in progress under their highly productive cardiometabolic renal disease collaboration with AstraZeneca. And Biogen initiated a aspect 1/2 study of IONIS-C9Rx, their second familial ALS drug which is in addition to IONIS-SOD1Rx, which is in a aspect 1/2 study in familial ALS and patients with SOD1 mutation with data expected in Q1 2019.

    As shown on this slide, they successfully completed many key milestones this year. In the fourth quarter and into 2019, we're looking forward to numerous essential catalysts including several regulatory decisions, data readouts and study initiations. They furthermore contemplate forward to discussing many of these events at their Investor Day in December.

    And now, I will circle the convene back over to you, Stan.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    Thank you, Brett. So, the third quarter was another very tenacious quarter for the company. They continue to demonstrate the power of the financial model that they built with continuing financial energy even while launching TEGSEDI and preparing the launch of WAYLIVRA. So, they are -- they continue to subsist substantially profitable and they believe they are positioned for continued growth.

    We believe WAYLIVRA demonstrates a positive benefit/risk profile for patients suffering with FCS with no therapeutic options. Regulatory process continued in the EU, and they are in conversations with the FDA and Canadian authorities as well. Akcea is ready to launch WAYLIVRA as quickly as viable once they believe approval in the EU and other territories.

    We believe a number of near-term value drivers including plans to initiate at least three pivotal studies before the conclude of the year. These are programs with the potential to change of course deadly genetic diseases, such as Huntington's disease, TTR amyloidosis, as well as diseases that affect millions of patients such as Lp(a) driven cardiovascular disease. They furthermore believe multiple mid-stage programs in a number of therapeutic areas that we're excited about which believe the potential to drive longer-term growth. They contemplate forward to discussing more about these programs as they progress.

    With that, I'll circle the convene over to Cole to set us up for mp;A. Cole, would you gladden set us up?

    Questions and Answers:

    Operator

    Certianly. They will now initiate the question-and-answer session. (Operator Instructions) Their first question comes from Tyler Van Buren with Piper Jaffray. gladden proceed ahead with your question.

    Tyler Van Buren -- Piper Jaffray -- Analyst

    Good morning, guys. Thanks for taking my question. I guess, the first one was with respect to the TEGSEDI REMS program, specifically regarding logistics for docs who aren't I guess as confidential with the REMS programs how facile is it going to subsist for them to badge up? What specifically accomplish they believe to do? How are you guys helping them? And how long could that take? I noticed that some of the questionnaires online are actually quite simple with less than 10 questions, but just wanted to better understand that process.

    Damien McDevitt -- Chief trade Officer

    Yes. So, thank you for your question, Tyler. So, this is why we've set up Akcea Connect to assist physicians and patients toil through the paperwork associated with the REMS program. So, as you spotted, it's very straightforward going through these paperwork. And to date, there's been no issues. We've had physicians and patients certified through REMS and registered on Akcea Connect.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    Just to add to that Tyler, I actually went through the process myself, and so there was a lot of endeavor at reducing the tribulation everywhere on the patient, on the physician and the physician's office. And so I feel very, very uncomfortable with how facile it is to enroll in the program that Akcea has set aside together. I assume it's quite an exciting foster in managing these processes.

    Tyler Van Buren -- Piper Jaffray -- Analyst

    That's great. Are you able to bid how many doctors are certified on the REMS or how many patients are on the REMS?

    Damien McDevitt -- Chief trade Officer

    No, we're not providing numbers. They believe had patients and physicians certified to-date, but we're not giving out the exact numbers at this point.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    We're encouraged by what received. We're encouraged by what received.

    Tyler Van Buren -- Piper Jaffray -- Analyst

    Okay. And the second question was with respect to the platelet monitoring. I guess, I'm assuming that the samples need to subsist taken by a nurse and that the patient can't accomplish it themselves, or maybe you can amend me if I'm wrong, but specifically and logistically, how will it happen? How long will it take? And if someone is on a trade trip how would you rep their platelet levels monitored on a weekly basis?

    Damien McDevitt -- Chief trade Officer

    So, the patient -- the platelet monitoring will happen, the blood draws will subsist done at home, and with nurses, and so does that help.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    So, platelet monitoring is designed so it will subsist as convenient as possible. We'll proceed where the patient wants us to go. The patient is near a lab and they prefer going in and getting their blood drawn there. noteworthy if they are traveling, why, of course, there are clinical laboratories everywhere, (inaudible) so that the patient can proceed there and rep the job done. And of course we're providing the opportunities to believe the platelets determined or blood drawn in, in the home as well. At least, once a week, it's over in a matter of just a yoke of minutes. It's rapid easy. Certainly, speaking for myself, I would rather accomplish that and proceed to an infusion heart and expend a day getting an IV infusion.

    Tyler Van Buren -- Piper Jaffray -- Analyst

    Yes. And that makes sense. I guess if you're having nurses proceed to the patient's home or if they're on a trade trip and wherever location they are, don't you guys believe to believe a lot of nurses on staff or subsist plugged into some large network? Just I guess nosy to hear a dinky bit about that.

    Damien McDevitt -- Chief trade Officer

    Yes. So, when they are plugged into the large network and through Accredo, there are 600 nurses on staff throughout the US. So that's fairly large network available.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    And Quest. Of course, they believe a partnership with Quest, so that there's a lab. It's not Starbucks, but it's almost Starbucks, except the lines are shorter.

    Tyler Van Buren -- Piper Jaffray -- Analyst

    Great. Thanks a lot for taking the questions.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    You bet.

    Operator

    And their next question comes from Paul Matteis with Stifel. gladden proceed ahead with your question.

    Ben Burnett -- Stifel -- Analyst

    Hi. Thank you. This is Ben Burnett on for Paul Matisse. Just a question on the SOD1 program, the upcoming readout here. Can you discuss what flush of knockdown you would constitute as adequate as supportive of advancing the program? And then I guess secondly, are you able to converse to the flush of enrollment to the extension study? And I guess, can you just remind us of the regulatory path forward for this assuming positive data in 2019? Thank you.

    Brett P. Monia -- Chief Operating Officer and Senior Vice President, Translational Medicine

    Yes. This is Brett. I will pick that convene -- that question. So, as I assume you inferred, they can measure SOD1 levels. They validated SOD1 levels in the CSF much fancy they did for the Huntington program, where they were able to demonstrate market reductions in the CSF for Huntington. So that will subsist Part of the clinical study. It's a three-month study in patients with symptomatic ALS with SOD1 mutations. And based on a pre-clinical data, they can -- that reductions on the order of 30% to 50% much fancy Huntington believe shown significant capitalize in animal models of SOD1 ALS. In fact those types of reductions believe shown complete halting of disease progression in SOD1 animal models.

    Regarding the study, the study is enrolled. And we're looking at data readout in the first quarter of next year. And as for regulatory path, it's hard to say, how they remark the data. But as I mentioned, the study design is very similar to the Huntington study. And as you know, the Huntington study went from aspect 1 to pivotal aspect 3 study. So, it's not outside the wrong possibility that based on the data that comes out, Biogen would inch in that direction.

    Ben Burnett -- Stifel -- Analyst

    Thanks Brett.

    Wade Walke -- Vice President, Investor Relations

    Next question please.

    Operator

    And their next question comes from Chad Messer with Needham & Company. gladden proceed ahead with your question.

    Chad Messer -- Needham & Company -- Analyst

    Great. Thanks. Thanks for taking my question. I believe one on danvatirsen, the STAT3 program. What can they await from that next maybe in terms of other indications? And any view when that might combine the ranks of aspect 3 along with some of the other programs?

    Brett P. Monia -- Chief Operating Officer and Senior Vice President, Translational Medicine

    Thanks, Chad. So, thanks for the question. Yes, their immuno-oncology program -- their oncology program in common is really showing a lot of noteworthy potential. Their STAT3 leads the way. It was their first-generation 2.5 molecule to enter the clinic. And we've recently with AstraZeneca recently reported very encouraging results as I highlighted in the script in the presentation they just gave in patients with refractory head and neck cancer in combination with durvalumab. That study -- that drug in that combination has furthermore now started a uniform non-small cell lung cancer, so that's another indication to your question, and bladder cancer. And AstraZeneca is exploring other oncology indications produced for this program.

    AstraZeneca is collecting more and more data in this study, in the second line refractory study, as well as in first line head and neck cancer patients in combination with durvalumab. And over the next few months, they're planning to construct a determination on the next stage of progress for the program in the head and neck cancer which could certainly subsist a pivotal study.

    Chad Messer -- Needham & Company -- Analyst

    Thanks, Brett.

    Operator

    And their next question comes from Gena Wang with Barclays. gladden proceed ahead with your question.

    Gena Wang -- Barclays -- Analyst

    Thank you for taking my questions. One question regarding SPINRAZA, I know the World Muscle, foster data was very impressive. Just wondering what will subsist the next step to expand label to the pre-symptomatic patients? And then a very quick question regarding the WAYLIVRA, any plot for the FDA regulatory path for the next step?

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    Thanks. The SPINRAZA label supports administration of SPINRAZA to patients of any sort with SMA. And certainly more and more babies are being treated presymptomatically because the data are so overwhelmingly positive. So that's happening as they speak.

    Damien McDevitt -- Chief trade Officer

    And, of course, just to add to that Stan, as you know Gena, the newborn screening has incorporated now officially nationally SMN2 as a genetic measurement in the newborn screen panel to identify the patients that are presymptomatic that will develop SMA. And now that's becoming incorporated into a statewide system and nationally as well. So everything this bodes very well for treating more and more patients presymptomatically both the genetic testing as well as the data, the foster data that was presented in World Muscle.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    The other thing that's sort of been forgotten, but it's tremendously impressive to me is that it's not just in the foster study that they remark would continue to -- treatment patients continue to rep better and better. We're seeing the same sort of deportment in less austere infants and infants that are treated asymptomatically and we're seeing it in the ilk two and the adult patients as well. So, today SPINRAZA has delivered incredible value. And the longer they treat, the better it is for essentially everything the patient types that believe been treated with SPINRAZA. So, it looks quite exciting.

    Wade Walke -- Vice President, Investor Relations

    Next question.

    Operator

    Our next question comes from Jessica Fye with JP Morgan. gladden proceed ahead with your question.

    Jessica Fye -- JPMorgan -- Analyst

    Great, and thanks for taking my questions. Can you assist us assume about when they could remark extension data from the Huntington's aspect 1/2 trial? I assume clinical trials fancy I've said it's 14 months of treatment with completion in December of 2019. Is it viable they could remark incremental update sooner given that it's open label? furthermore can you talk to the dose levels and dosing frequency in that extension trial?

    Brett P. Monia -- Chief Operating Officer and Senior Vice President, Translational Medicine

    Sure, Jess. Roche is not -- well the open label extension study is going very well. everything the patients are obviously enrolled into the study, and they're in the study. They are continuing to subsist treated, and it's going well as I said. Roche has been very transparent, and has worked very closely with patient advocacy, patients, doctors, physicians, and has been very transparent in the information they've provided. They haven't said specifically when and in what cadence they're going to actually partake data from the open label extension, but they believe that they'll subsist sharing data over the course of 2019 because it's so essential to the patient community to partake that data and know how the program is going. The dosing is the same as it was in aspect 1/2 which is monthly dosing, and they're administering the top dose and that was from the aspect 2 study.

    Jessica Fye -- JPMorgan -- Analyst

    Okay. And apologies, if I missed this, but for the two-year aspect 3s for that product, what specifically will subsist the primary clinical efficacy endpoint?

    Brett P. Monia -- Chief Operating Officer and Senior Vice President, Translational Medicine

    So the clinical endpoints are now -- believe been disclosed by Roche. They're going to involve both cognitive measures, motor function measures, autonomic (ph) measures of neurological functions as well as MRI scans of brain size, and those sorts of things, quality-of-life measures. It's a composite scoring system that we're using in US and EU. It is slightly different in US and EU, and but it's now been fully vetted through the FDA, the EMA and it's been posted.

    Jessica Fye -- JPMorgan -- Analyst

    Okay. Great. And eventual one for me is just Novartis made some comments yesterday that they are not especially focused on combining splice modulators with gene therapy and SMA. So just nosy as the leader in SMA what was your reaction to that view?

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    Well, they are leaders in SMA, and they accomplish assume that there are opportunities in the future to exercise a variety of agents in combination. Whether a gene therapy agent would add any value to SPINRAZA given the results that they believe is hard for me to know today. So, we're watching the progression of the gene therapy as well as miniature molecule. And if there appears to subsist some spot in which SPINRAZA doesn't bring sort of remarkable value, I'm sure, that Biogen and others will contemplate at combinations. There's nothing to preclude any combination with any of the drugs that are in progress that we're cognizant of.

    Jessica Fye -- JPMorgan -- Analyst

    Okay, great. Thank you.

    Operator

    And their next question comes from Jim Birchenough with Wells Fargo. gladden proceed ahead with your question. Mr. Birchenough (multiple speakers).

    Yanan Zhu -- Wells Fargo -- Analyst

    Yeah. Sorry about that. Thanks. This is Yanan in for Jim. So first question regarding SPINRAZA revenues, could you narrate the driver for the growth? Is it patient number or some other factors such as change in the early patients pile schedule versus longer intervals in previously enrolled patients? So, any color on that?

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    It's patient numbers. There hasn't been any change in dosing schedule. So what's happening is that more patients are being treated, and the patients that believe been treated are continuing to subsist treated. So it's -- I assume just correlates with benefit. More patients are being treated and more patients are being treated longer.

    Yanan Zhu -- Wells Fargo -- Analyst

    Got it. And you described an extend in adult patients. Would you subsist able to comment whether the pediatric patients whether that portion of the market is stable? Yeah.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    It continues to grow.

    Yanan Zhu -- Wells Fargo -- Analyst

    Got it. And you were just talking about the combinations -- potential combination the possibility with gene therapy between SPINRAZA and gene therapy. I thought Novartis mentioned a expense tag of $4 million to $5 million for their gene -- potentially for their gene therapy. How does that -- what's your view on that, and how might that repercussion the faculty to combine the two drugs?

    Damien McDevitt -- Chief trade Officer

    Well, I assume it's early days. And I assume I'll let Novartis discuss their pricing and its repercussion on whether patients of sort uses drug, and whether -- would construct sense to combine it. At that expense obviously any combination would believe to panoply an extraordinary capitalize compared to SPINRAZA. That's going to subsist very difficult to accomplish given the fact that the vast majority of presymptomatic patients who were treated are developing fancy established children. How accomplish you accomplish better than that?

    Yanan Zhu -- Wells Fargo -- Analyst

    Got it. And the eventual question on the Huntington's disease trial -- aspect 3 trial design by Roche. Would you subsist able to comment on whether the aspect 3 study the 660-patient study would that subsist a controlled or uncontrolled study?

    Damien McDevitt -- Chief trade Officer

    It's 660 and it's a controlled study, yes.

    Yanan Zhu -- Wells Fargo -- Analyst

    Got it. Thank you.

    Operator

    And their next question comes from Vincent Chen with Bernstein. gladden proceed ahead with your question.

    Vincent Chen -- Bernstein -- Analyst

    Great. Thank you very much for taking the question. So, I guess, one question about SPINRAZA and sort of the future of the SMA market, how are you and your partners with Biogen thinking about defending against Roche's oral compound in SMA for instance whether that's next-generation agents with profiles pile up with the SPINRAZA and trying to demonstrate areas of potential superiority whether with SPINRAZA or follow-on potentially using the novel biomarkers, et cetera? Could you just provide us with more color on how you assume about a market defense strategy here?

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    Well, I assume the first order of trade is to continue to learn more about SPINRAZA. And today the more they learn the better the drug appears to subsist in everything patients. Second, of course, they are collaborating with Biogen to contemplate at a new -- various follow-ons to SPINRAZA that might believe lower doses or might believe less frequent dosing. I assume it's -- what I assume needs to chance now, before they comment on whether oral agents might subsist used, might subsist used in combination and how they might subsist used is one to watch how SPINRAZA does over the next year. They continue to watch that. And then second, to evaluate these -- the clinical trials that are in progress both in terms of capitalize and safety. I think, there's not very much yet really know about the miniature molecule drugs and we're looking forward to seeing the data.

    Vincent Chen -- Bernstein -- Analyst

    Thank you.

    Operator

    And their next question comes from Ritu Baral from Cowen. gladden proceed ahead with your question.

    Ritu Baral -- Cowen & Company -- Analyst

    Hi, guys. Thanks for taking the question. Going back to the Huntington's endpoint, the aspect 3 endpoint that they were talking about before, I assume you guys mentioned, it was a composite cognitive motor functions autonomic, MRI volume and character of life. How are those weighted within the composite? Is there any requirement for one component to panoply unavoidable threshold sequel for that composite endpoint to subsist positive? How does that primary endpoint work?

    Damien McDevitt -- Chief trade Officer

    Yes. Ritu, they will believe to -- I don't believe those details in front of us on how the various components to the composite score are weighted. Why don't they rep back to you on that?

    Ritu Baral -- Cowen & Company -- Analyst

    Sure. And then a quick follow-up on WAYLIVRA in Europe. Can you remind us where you are on that process? believe you received fancy the 120-day questions as they progressed -- as there believe been progress made between 120 and 180 days? Any details that you can share?

    Damien McDevitt -- Chief trade Officer

    We're late in the process. They accomplish -- we've had a number of meetings and conversations and responses to a variety of questions 120-day and others. So we're late in the process and we're looking forward to bring it to a conclusion here in the next quarter.

    Ritu Baral -- Cowen & Company -- Analyst

    Got it. And apologies if I just wasn't writing rapidly enough here. You accomplish believe commercial patients on TEGSEDI. I know you believe German commercial patients treated. accomplish you believe US commercial patients treatment already started? Or is that going to subsist imminent given accretive just got it licensed?

    Damien McDevitt -- Chief trade Officer

    Yes. Thanks, Ritu. They believe patients and physicians that are certified through REMS and registered on Akcea Connect. And they believe specialties -- their specialty pharmacy certified through REMS as well and is up and running. And they believe meetings with physicians and their teams and they received the first set of scripts. That's where they are today.

    Ritu Baral -- Cowen & Company -- Analyst

    Got it. Okay. That's helpful. And then I guess eventual question is -- sorry, the conclude of aspect 2 meetings that you and Novartis will believe on Lp(a), given that we're everything expecting just sort of a really plain vanilla monotonous endpoint aspect 3. Are there other topics to discuss any aspect of the compound or Lp(a) that are worth noting outside just the simple relatively monotonous aspect 3 time?

    Brett P. Monia -- Chief Operating Officer and Senior Vice President, Translational Medicine

    That's the first time I've heard an outcome study described as relatively boring, but OK. We're kindhearted of excited about it, and I think, I'll just leave it there. It's a obliging question, but it's a dinky more detailed than I assume would subsist commandeer to proceed into here. I'm positive that once they believe the meeting that they believe to discuss everything that in a dinky more detail. I will cheer everyone to construct the late-breaker that's coming this Saturday that Sam Tsimikas is presenting. We're really, really excited about the data they believe to partake both in terms of the potency of the agent as well as the safety tolerability. And so they contemplate forward to being able to partake much more detailed data with the community.

    Ritu Baral -- Cowen & Company -- Analyst

    Got it. Thanks for taking everything the questions.

    Brett P. Monia -- Chief Operating Officer and Senior Vice President, Translational Medicine

    You bet.

    Operator

    And their next question comes from I-Eh Jen with Laidlaw & Company. gladden proceed ahead with your question.

    Yale Jen -- Laidlaw & Company -- Analyst

    Thanks a lot for taking the questions. And I assume a lot believe been answered, I've got two here. The first one is that for the NASH you believe two data releases later both regarding the NASH. One is the DGAT2 and the other is the ANGPTL3. Could you differentiate the specific indications that these two drop may believe a target.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    Yes, that is a very engrossing question. They believe quite a pipeline of different agents focused on either the lipid component of NASH or the fibrotic component of NASH or everything the above. The way I assume of DGAT2 is that it's highly specific to reduce triglycerides in the liver. And so they assume of it as a very specific reagent that should believe a towering substantial capitalize in liver fab without any of the sort of issues that trying some of the other drugs such as increasing LDL and that sort of thing. With ANGPTL3 that's a common dyslipidemia agent in their mind. They know that it lowers LDL, they know that it lowers triglycerides. They know that it lowers ApoB100.

    And so in the study that we're conducting we're asking you the question, does that translate to a significant reduction in triglycerides in the liver? And then we'll contemplate at the composite capitalize of that drug grams. It could subsist a candidate for exercise as a common agent to reduce triglycerides in people with moderately elevated triglycerides. It could subsist used to treat patients with a broad compass of dyslipidemias and it could subsist used to treat NASH. So if you assume about DGAT2, is a very selective and specific liver triglyceride drug primarily, and ANGPTL3 is more a common dyslipidemia drug with NASH as break among the several that they will pursue. That will subsist the way I assume about it.

    Yale Jen -- Laidlaw & Company -- Analyst

    So would that subsist -- may subsist in more specific to bid that was targeting to a early disease process of the NASH, but not necessarily into the fibrosis progress into the fibrosis condition?

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    Well, that's correct. These two drugs are focused on the lipid which is the driver of the disease, and so they believe that as they lower the liver triglycerides, they will affect the progression of the disease and reduce the progression of disease. They believe other agents that are coming that are focused on the fibrotic Part of the process as well. So what they are going to subsist doing over the next dinky bit, is looking at the data that they believe in each of these drugs and sliding down for the best patient population for each of the drug. They assume this Part of -- this component of their pipeline is really quite exciting.

    Yale Jen -- Laidlaw & Company -- Analyst

    Maybe one more question --

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    And it furthermore demonstrates the power of antigens. They can create selective drugs to target different targets, different parts of pathways, different parts of causes of these intricate multi-factor diseases. And then let the data converse and divulge us where they should subsist positioned each one of their opportunities.

    Yale Jen -- Laidlaw & Company -- Analyst

    Yes, maybe one more question regarding the Huntington disease. You bid there's two studies and the first study mainly focus on the reduction of the Huntington proteins. And -- but that study you're furthermore monitoring some kindhearted of symptomatic differences over times and maybe believe some sort of readout even before the second study is fully enrolled. Is that the plot or does that.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    No, that's correct. That's the open label extension and they are encouraged by what we've been seeing. And as Brett said, they accomplish believe that Roche will subsist providing updates on the progress in that study in 2019 although I can't converse for Roche in more detail.

    Yale Jen -- Laidlaw & Company -- Analyst

    And does the drug believe two different -- there is a cohort A and B is at different flush of the -- as that minister to subsist administrated.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    I assume the open label extension is going simply at the highest dose.

    Damien McDevitt -- Chief trade Officer

    Correct.

    Yale Jen -- Laidlaw & Company -- Analyst

    Okay. Great. Thanks a lot. I esteem it.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    You bet.

    Operator

    And their next question comes from David Lebowitz with Morgan Stanley. gladden proceed ahead with your question.

    David Lebowitz -- Morgan Stanley -- Analyst

    Thank you very much for taking my question. With respect to TEGSEDI reimbursement, could you elope us through I guess what types of -- what pieces of information payers in the early elope believe requested regarding patients and discovering the reimbursement process understanding that you haven't actually finished the whole process yet with patients?

    And then beyond that, what is your expectation for turnaround time from when a patient initially meets with the doctor regarding potentially getting prescribed TEGSEDI to genesis the REMS process and eventually becoming paid and reimbursed it on drug?

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    I'm going to intimate that you address those questions primarily to Akcea. There are a lot of detail in the process. I can give you my sense of what I understand. I know that their colleagues at Akcea believe met with many payors before and after launch. And the focus of payors was sort of where you would await it to subsist in the capitalize versus the cost. And I understand that those conversations believe gone extremely well.

    And the Akcea Connect program is really a very robust highly focused on getting patients into treatment with the easiest process and the shortest time possible, and facilitating the practitioners' entry into the treating of the patient and taking edge and taking supervision of the time of the practitioner who manage these patients.

    So, it's short, but I can't divulge you the exact time between start and finish. And I suspect that they really won't know for a while just how it's everything going to toil until they did a lot more experience. And I'm positive as they gain experience, we'll subsist able to subsist even abbreviate it further.

    David Lebowitz -- Morgan Stanley -- Analyst

    Thank you very much for taking my question.

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    Yes. If that is the eventual question, so I'd fancy to bring the convene to a close. Once again, thanks everyone for joining us today. I very much esteem your interest and the questions that you've asked. They cheer you to wait tuned for APO(a)-LRx deal that will subsist presented in more detail this Saturday at AHA. And they contemplate forward to seeing you at their Investor Day in new York in which we'll believe the break to provide a significant -- significantly greater update on essentially everything that we're doing.

    What they are really excited about is that we're progressing to commercializing their two new drugs while SPINRAZA continues to accomplish well, advancing their pipeline continuing to foster the technology. We're witnessing the improvements in the technology being manifested in the performance of their drugs across the board, and we're doing everything that while we're growing operating profits and we're cash accretive. They assume that's an exciting story, and we're looking forward to telling it in more detail in their Investor Day. Thanks very much.

    Operator

    The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.

    Duration: 61 minutes

    Call participants:

    Wade Walke -- Vice President, Investor Relations

    Stanley T. Crooke -- Chairman of the Board & Chief Executive Officer

    Elizabeth L. Hougen -- Senior Vice President, Finance & Chief financial Officer

    Damien McDevitt -- Chief trade Officer

    Brett P. Monia -- Chief Operating Officer and Senior Vice President, Translational Medicine

    Tyler Van Buren -- Piper Jaffray -- Analyst

    Ben Burnett -- Stifel -- Analyst

    Chad Messer -- Needham & Company -- Analyst

    Gena Wang -- Barclays -- Analyst

    Jessica Fye -- JPMorgan -- Analyst

    Yanan Zhu -- Wells Fargo -- Analyst

    Vincent Chen -- Bernstein -- Analyst

    Ritu Baral -- Cowen & Company -- Analyst

    Yale Jen -- Laidlaw & Company -- Analyst

    David Lebowitz -- Morgan Stanley -- Analyst

    More IONS analysis

    Transcript powered by AlphaStreet

    This article is a transcript of this conference convene produced for The Motley Fool. While they strive for their absurd Best, there may subsist errors, omissions, or inaccuracies in this transcript. As with everything their articles, The Motley Fool does not assume any responsibility for your exercise of this content, and they strongly cheer you to accomplish your own research, including listening to the convene yourself and reading the company's SEC filings. gladden remark their Terms and Conditions for additional details, including their Obligatory Capitalized Disclaimers of Liability.

    SPONSORED: 10 stocks they fancy better than Ionis Pharmaceuticals

    When investing geniuses David and Tom Gardner believe a stock tip, it can pay to listen. After all, the newsletter they believe elope for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*

    David and Tom just revealed what they believe are the 10 best stocks for investors to buy prerogative now... and Ionis Pharmaceuticals wasn't one of them! That's prerogative -- they assume these 10 stocks are even better buys.

    Click here to learn about these picks!

    *Stock Advisor returns as of August 6, 2018

    Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Ionis Pharmaceuticals. The Motley Fool has a disclosure policy.


    District 181 Welcomes new Staff Members for 2012-13 | killexams.com true questions and Pass4sure dumps

    This post was contributed by a community member.

    New Administrators (alphabetical by eventual name)

     Christine Cagney (Principal, Walker School) has a B.S. in trade Administration from Fordham University, as well as an M.A. in Teaching in Special Education and an M.Ed. in Administration and Supervision, both from National Louis University. Ms. Cagney was an assistant Principal at Hunting Ridge Elementary School in Palatine Community Consolidated School District 15 for two years and was a special education teacher in Woodridge School District 68 for four years.

    Deborah Doyle (Pupil Services Administrator) has 16 years of suffer in schools. Ms. Doyle worked for eight years in Naperville Community Unit School District 203 as an assistant Director for Pupil Services and as an assistant Principal, one year in Birmingham Schools as a Special Education Department Chair, two years in Clarkston Community Schools as a Supervisor of Student advocate Services and a middle school special education teacher, one year as a special education teacher in Downers Grove, and four years as a special education teacher in Lockport. She earned a B.S. in Special Education from the University of Wisconsin - Oshkosh and an M.A. from Governors condition University.

    Gary Frisch, CPA (Assistant Superintendent for Business) comes to District 181 with 25 years of suffer in school trade management, including 19 years as the chief school trade official. Mr. Frisch most recently worked at Barrington Community Unit School District 220 and in Glenbard Township towering School District 87. He serves as an adjunct professor at Aurora University and Concordia University, teaching graduate courses in school finance and school ethics. Mr. Frisch earned his B.S. in trade Administration from Illinois condition University – established and his M.S. in School trade Management from Northern Illinois University – DeKalb. Mr. Frisch has a ilk 75 certificate and Chief School trade Official endorsement.

    Casey Godfrey (Principal, The Lane) had been principal of Fairmount Elementary School in Francis Howell School District in Missouri for the past three years. Prior to that, Mr. Godfrey worked in the Lincoln County R-III School District in Missouri, where he was a teacher and later a principal of Hawk Point Elementary. He began his career in education as a 4th and 5th grade teacher at William Cappel Elementary. He has an M.Ed. from Lindenwood University in Missouri, in addition to a B.S. in Elementary Education from Murray condition University in Kentucky.

    Bridget McGuiggan, APR (Director of Communications) served as the Community Relations Coordinator at Orland School District 135 for six years before joining District 181 in July. Prior to working in Orland 135, she was the Coordinator of Marketing and Public Relations at Queen of Peace towering School, her alma mater. Her B.S. is in Mass Communications and Marketing, earned from Saint Joseph's College in Indiana. Additionally, she has earned Accreditation in Public Relations (APR) and is Past President of the Illinois Chapter of the National School Public Relations Association.

    Dr. Kurt Schneider (Assistant Superintendent for Learning (Pupil Services)) comes to District 181 from Wisconsin, where he had been the Co-Administrator of Teaching and Learning, Director of Student Services, for the Stoughton belt School District for the past eight years. Dr. Schneider began his career as a towering school special education teacher at Madison East towering School. He has served as an adjunct university instructor for graduate and undergraduate courses in the Departments of Educational Leadership and Policy Analysis and Rehabilitation Psychology and Special Education at the University of Wisconsin-Madison, and furthermore at Edgewood College in Madison. He earned a doctorate in educational administration, a master's degree in special education and a bachelor's degree in special education, everything from the University of Wisconsin - Madison.

    New Teachers, Interventionists, Therapists (Alpha by Last)

     Kristi Awtry (Resource, HMS (.5FTE)) returns to District 181 this year after serving as a long-term substitute. Her suffer includes toil at Elm, Oak, and HMS, in addition to four years of suffer in the Oklahoma belt with Pre-K, 1st grade, and 7th and 8th grade students. She has a B.S. in Elementary Education from the University of Central Oklahoma and has completed coursework in the special education field and earned a Learning deportment Specialist I endorsement.

    Karen Berman (ECE, Sp. Ed., Oak) is no stranger to Early Childhood Education, with suffer in Early Childhood programs in both Waukegan and Palos Heights schools. She has a B.S. in Early Childhood Education and an M.Ed. in Early Childhood Special Education, both from the University of Illinois at Urbana-Champaign. Ms. Berman has furthermore earned a Learning deportment Specialist I endorsement.

    Kathryn Cox (Science / Language Arts, Grade 6, CHMS) holds a B.A. in Elementary Education with a minor in Biology from Elmhurst College, where she graduated with Highest Honors and was a member of the Kappa Delta Pi honor Society. Ms. Cox has seven years of suffer in schools, including one year with Keeneyville Elementary School District 20 in Roselle and six years with District 181 at both CHMS and HMS.

    Jessica Czerniuk (P.E., Madison (.94FTE)) will bring suffer in Physical Education from two previous districts when she comes to Madison. Ms. Czerniuk was a P.E. teacher in South Holland School District 151 and Maercker School District 60. She has a B.A. in Kinesiology and Physical Education from Northern Illinois University and an M.A. in Curriculum and Instruction from Olivet Nazarene University.

    Jennifer Duffy (Assistive Technology, District-wide (.5FTE)) will expend time in everything District 181 schools through her role in Assistive Technology. She earned a B.A. in Special Education from Northern Illinois University and has completed coursework related to brain-based learning and technology for students with disabilities. Ms. Duffy previously worked for the Kendall County Special Education Cooperative and in Indian Prairie School District 204, serving students in Aurora and Naperville. Ms. Duffy is currently a Literacy Consultant for Gretchen Courtney & Associates, Ltd.

    Erin Eder (School Psychologist, District-wide) holds a B.S. in Psychology from the University of Illinois Urbana-Champaign and an Educational Specialist degree in School Psychology from National-Louis University. Her previous toil suffer includes three years as a school psychologist with the Southern Will County Cooperative for Special Education.

    Jean Fitzgerald (Art / Computer Graphics / MS Skills, CHMS (.5FTE)) is a winner of the 2011 Hillbrunner Artists bespeak Fellowship through the School of the know-how Institute of Chicago, where she earned an M.A. in teaching. Ms. Fitzgerald furthermore holds a B.F.A. in Painting from the University of Michigan.

    Laura Ghera (Music, Monroe) comes to District 181 with suffer as a chorus and common music teacher, with time spent in Butler School District 53, Geneva Community Unit School District 304, and Lisle Community School District 202. She furthermore taught e-Learning for District 53. Mrs. Ghera earned a B.A. in Vocal Performance and Hispanic Studies from Illinois Wesleyan University and an M.M.Ed. from the VanderCook College of Music.

    Karen C. Johnson (Balanced Literacy Coach, District-wide) will toil with students at everything grade levels through her role as a Balanced Literacy coach. With a B.A. from Northeastern Illinois University, an M.A. in Reading from National Louis University, a Learning deportment Specialist endorsement, and training in Reading Recovery, Ms. Johnson is ready to succeed in District 181. Her suffer includes toil in Naperville Community Unit School District 203 and Plainfield Community Consolidated District 202, where she earned an award from the Coordination of Administration and Parents Groups for Educational Efficiency.

    Dr. Kathy Kula (School Psychologist, District-wide) holds a B.S. in Psychology and Sociology from the University of Illinois at Urbana-Champaign and an M.A.T. in Elementary Education from Dominican University, as well as an M.Ed. in School Psychology and a Ph.D. in School Psychology, both from Loyola University Chicago. Dr. Kula's previous toil suffer includes an internship with Park Ridge-Niles School District 64, a specialty practicum at Edwin G. Foreman towering School, and a practicum at Morton West towering School. She furthermore taught 6th and 7th grade math, science, and convivial studies at the Chicago International Charter School in Washington Park.

    Justine Legner (3rd Grade, Prospect) taught math and reading at District 181's The Lane and holds a B.A. in K-9 Elementary Education from North Central College.

    Cherise Madden (Resource, Elm (.5FTE)) earned a B.A. in Elementary Education from Elmhurst College and an M.A. Reading Specialist degree from National Louis University. Ms. Madden furthermore holds a Certificate of Advanced Instruction in Special Education. Her background includes teaching 1st grade in Melrose Park, 2nd and 3rd grade in Elmwood Park, and kindergarten, 1st grade, and 2nd grade for St. Giles School in Oak Park.

    Juliette Nardulli (Resource, Oak) is currently working toward an M.A. Reading Specialist degree from Concordia University. Mrs. Nardulli earned a B.A. in Elementary Education from Benedictine University and holds a Learning deportment Specialist endorsement from Roosevelt University. Mrs. Nardulli's suffer includes teaching 1st grade and kindergarden at Kingswood Academy in Darien. She furthermore taught 4th grade at Noonan Academy in Mokena. Mrs. Nardulli served as an instructional aid at Oak and as a long-term substitute in Monroe and Madison Schools in District 181 in the 2011-12 school year.

    Meg Neubauer (Social Worker, Madison) earned both a Bachelor's and Master's degree in convivial toil from Loyola University, where she furthermore earned a B.A. in Sociology. Ms. Neubauer holds a ilk 73 certificate, as well. She has been an Early Childhood convivial Worker in McHenry School District 15 and in the LaGrange belt Department of Special Education (LADSE).

    Margo Rodenbostel (Social Studies, CHMS (.33FTE)) worked in District 181 for three years before returning now as a 6th grade convivial studies teacher at CHMS. She has a B.A. in International Relations from the University of Wisconsin – Madison and an M.A. in Education from DePaul University.

    Ele Santini (Social Worker, CHMS) has a B.A. and an M.A. in convivial toil from the University of Illinois at Chicago, in addition to a ilk 73 certificate. She is a Licensed Clinical convivial Worker and Accredited Case Manager, as well. Ms. Santini served as a convivial worker for 11 years in a medical setting and furthermore interned as a convivial worker at HMS.

    Chris Taylor (Intermediate (3-5), Monroe) has an M.A. in Teaching with Certification from Aurora University and earned a Learning deportment Specialist I endorsement. Mr. Taylor worked for two years in Elmhurst Community Unit School District 205 as a 5th grade teacher. He furthermore taught 5th grade in Plainfield Community Consolidated School District 202.

    Lindsay Wagner (4th Grade, Oak) comes to District 181 from the Colorado area, where she taught 4th and 5th grade literacy. She furthermore served as a long-term substitute for 4th grade at Oak in District 181 and furthermore in 1st and 4th grades in Western Springs District 101. Her previous toil suffer furthermore includes seven years in advertising. Mrs. Wagner earned a B.A. in Journalism and Mass Communications from the University of Iowa and has completed graduate toil towards an elementary license and an elementary literacy leadership endorsement at the University of Colorado at Denver.

    Patricia Ward (SLP for ECE, Oak) has an M.S. in Speech-Pathology from Marquette University and is certified in Neurodevelopmental Treatment. She is presently studying for Board Certified deportment Analyst certification in Applied Behavioral Analysis at the Chicago School of Professional Psychology. Ms. Ward previously worked for LaRabida Children's Hospital, Children's Memorial Hospital, and a private exercise in Orland Park, in addition to time in Naperville Community Unit School District 203. As a member of the American Speech-Language-Hearing Association, Ms. Ward was presented with the Award for Continuing Education in recognition of continued professional study.

    Aleisa Woodward (1st Grade, Oak) worked in Georgia's Whitfield County School System and then in Pleasantdale School District 107 in Burr Ridge, both for four years as a kindergarten teacher. Ms. Woodward most recently taught kindergarten and 2nd grade for one year each at The Lane. She has a B.S. in Early Childhood Education from the University of West Georgia.

    Polly Yukevich (Orchestra, District-wide) can divulge her new District 181 students about an exciting project she completed with a previous district, in which she implemented a $7,000 ukulele award and worked with world-renowned ukulele player Jake Shimabukuro. Ms. Yukevich furthermore led her students in a performance at the 2012 Illinois Music Educators Conference. Her previous districts include Glenview Public School District 34 and Community Unit School District 300. Ms. Yukevich holds a B.M.Ed. from the VanderCook College of Music and an M.M.Ed. from the University of Illinois at Urbana-Champaign.

    Previously Employed (Moving to Full-Time OR new Positions)

    The following individuals were previously employed in District 181 and believe moved positions for the 2012-2013 school year and/or moved from part-time to full-time: Doug Eccarius, Jamie Guerin, Ehren Hill, Meghan Kappmeyer, Justine Legner, Eileen Logan, Joan Rickert, and Kevin Russell.

    Get the Hinsdale-Clarendon Hills newsletterSubscribe

    Thanks for your feedback.



    Direct Download of over 5500 Certification Exams

    3COM [8 Certification Exam(s) ]
    AccessData [1 Certification Exam(s) ]
    ACFE [1 Certification Exam(s) ]
    ACI [3 Certification Exam(s) ]
    Acme-Packet [1 Certification Exam(s) ]
    ACSM [4 Certification Exam(s) ]
    ACT [1 Certification Exam(s) ]
    Admission-Tests [13 Certification Exam(s) ]
    ADOBE [93 Certification Exam(s) ]
    AFP [1 Certification Exam(s) ]
    AICPA [2 Certification Exam(s) ]
    AIIM [1 Certification Exam(s) ]
    Alcatel-Lucent [13 Certification Exam(s) ]
    Alfresco [1 Certification Exam(s) ]
    Altiris [3 Certification Exam(s) ]
    Amazon [2 Certification Exam(s) ]
    American-College [2 Certification Exam(s) ]
    Android [4 Certification Exam(s) ]
    APA [1 Certification Exam(s) ]
    APC [2 Certification Exam(s) ]
    APICS [2 Certification Exam(s) ]
    Apple [69 Certification Exam(s) ]
    AppSense [1 Certification Exam(s) ]
    APTUSC [1 Certification Exam(s) ]
    Arizona-Education [1 Certification Exam(s) ]
    ARM [1 Certification Exam(s) ]
    Aruba [6 Certification Exam(s) ]
    ASIS [2 Certification Exam(s) ]
    ASQ [3 Certification Exam(s) ]
    ASTQB [8 Certification Exam(s) ]
    Autodesk [2 Certification Exam(s) ]
    Avaya [96 Certification Exam(s) ]
    AXELOS [1 Certification Exam(s) ]
    Axis [1 Certification Exam(s) ]
    Banking [1 Certification Exam(s) ]
    BEA [5 Certification Exam(s) ]
    BICSI [2 Certification Exam(s) ]
    BlackBerry [17 Certification Exam(s) ]
    BlueCoat [2 Certification Exam(s) ]
    Brocade [4 Certification Exam(s) ]
    Business-Objects [11 Certification Exam(s) ]
    Business-Tests [4 Certification Exam(s) ]
    CA-Technologies [21 Certification Exam(s) ]
    Certification-Board [10 Certification Exam(s) ]
    Certiport [3 Certification Exam(s) ]
    CheckPoint [41 Certification Exam(s) ]
    CIDQ [1 Certification Exam(s) ]
    CIPS [4 Certification Exam(s) ]
    Cisco [318 Certification Exam(s) ]
    Citrix [47 Certification Exam(s) ]
    CIW [18 Certification Exam(s) ]
    Cloudera [10 Certification Exam(s) ]
    Cognos [19 Certification Exam(s) ]
    College-Board [2 Certification Exam(s) ]
    CompTIA [76 Certification Exam(s) ]
    ComputerAssociates [6 Certification Exam(s) ]
    Consultant [2 Certification Exam(s) ]
    Counselor [4 Certification Exam(s) ]
    CPP-Institue [2 Certification Exam(s) ]
    CPP-Institute [1 Certification Exam(s) ]
    CSP [1 Certification Exam(s) ]
    CWNA [1 Certification Exam(s) ]
    CWNP [13 Certification Exam(s) ]
    Dassault [2 Certification Exam(s) ]
    DELL [9 Certification Exam(s) ]
    DMI [1 Certification Exam(s) ]
    DRI [1 Certification Exam(s) ]
    ECCouncil [21 Certification Exam(s) ]
    ECDL [1 Certification Exam(s) ]
    EMC [129 Certification Exam(s) ]
    Enterasys [13 Certification Exam(s) ]
    Ericsson [5 Certification Exam(s) ]
    ESPA [1 Certification Exam(s) ]
    Esri [2 Certification Exam(s) ]
    ExamExpress [15 Certification Exam(s) ]
    Exin [40 Certification Exam(s) ]
    ExtremeNetworks [3 Certification Exam(s) ]
    F5-Networks [20 Certification Exam(s) ]
    FCTC [2 Certification Exam(s) ]
    Filemaker [9 Certification Exam(s) ]
    Financial [36 Certification Exam(s) ]
    Food [4 Certification Exam(s) ]
    Fortinet [12 Certification Exam(s) ]
    Foundry [6 Certification Exam(s) ]
    FSMTB [1 Certification Exam(s) ]
    Fujitsu [2 Certification Exam(s) ]
    GAQM [9 Certification Exam(s) ]
    Genesys [4 Certification Exam(s) ]
    GIAC [15 Certification Exam(s) ]
    Google [4 Certification Exam(s) ]
    GuidanceSoftware [2 Certification Exam(s) ]
    H3C [1 Certification Exam(s) ]
    HDI [9 Certification Exam(s) ]
    Healthcare [3 Certification Exam(s) ]
    HIPAA [2 Certification Exam(s) ]
    Hitachi [30 Certification Exam(s) ]
    Hortonworks [4 Certification Exam(s) ]
    Hospitality [2 Certification Exam(s) ]
    HP [746 Certification Exam(s) ]
    HR [4 Certification Exam(s) ]
    HRCI [1 Certification Exam(s) ]
    Huawei [21 Certification Exam(s) ]
    Hyperion [10 Certification Exam(s) ]
    IAAP [1 Certification Exam(s) ]
    IAHCSMM [1 Certification Exam(s) ]
    IBM [1530 Certification Exam(s) ]
    IBQH [1 Certification Exam(s) ]
    ICAI [1 Certification Exam(s) ]
    ICDL [6 Certification Exam(s) ]
    IEEE [1 Certification Exam(s) ]
    IELTS [1 Certification Exam(s) ]
    IFPUG [1 Certification Exam(s) ]
    IIA [3 Certification Exam(s) ]
    IIBA [2 Certification Exam(s) ]
    IISFA [1 Certification Exam(s) ]
    Intel [2 Certification Exam(s) ]
    IQN [1 Certification Exam(s) ]
    IRS [1 Certification Exam(s) ]
    ISA [1 Certification Exam(s) ]
    ISACA [4 Certification Exam(s) ]
    ISC2 [6 Certification Exam(s) ]
    ISEB [24 Certification Exam(s) ]
    Isilon [4 Certification Exam(s) ]
    ISM [6 Certification Exam(s) ]
    iSQI [7 Certification Exam(s) ]
    ITEC [1 Certification Exam(s) ]
    Juniper [63 Certification Exam(s) ]
    LEED [1 Certification Exam(s) ]
    Legato [5 Certification Exam(s) ]
    Liferay [1 Certification Exam(s) ]
    Logical-Operations [1 Certification Exam(s) ]
    Lotus [66 Certification Exam(s) ]
    LPI [24 Certification Exam(s) ]
    LSI [3 Certification Exam(s) ]
    Magento [3 Certification Exam(s) ]
    Maintenance [2 Certification Exam(s) ]
    McAfee [8 Certification Exam(s) ]
    McData [3 Certification Exam(s) ]
    Medical [69 Certification Exam(s) ]
    Microsoft [368 Certification Exam(s) ]
    Mile2 [2 Certification Exam(s) ]
    Military [1 Certification Exam(s) ]
    Misc [1 Certification Exam(s) ]
    Motorola [7 Certification Exam(s) ]
    mySQL [4 Certification Exam(s) ]
    NBSTSA [1 Certification Exam(s) ]
    NCEES [2 Certification Exam(s) ]
    NCIDQ [1 Certification Exam(s) ]
    NCLEX [2 Certification Exam(s) ]
    Network-General [12 Certification Exam(s) ]
    NetworkAppliance [36 Certification Exam(s) ]
    NI [1 Certification Exam(s) ]
    NIELIT [1 Certification Exam(s) ]
    Nokia [6 Certification Exam(s) ]
    Nortel [130 Certification Exam(s) ]
    Novell [37 Certification Exam(s) ]
    OMG [10 Certification Exam(s) ]
    Oracle [269 Certification Exam(s) ]
    P&C [2 Certification Exam(s) ]
    Palo-Alto [4 Certification Exam(s) ]
    PARCC [1 Certification Exam(s) ]
    PayPal [1 Certification Exam(s) ]
    Pegasystems [11 Certification Exam(s) ]
    PEOPLECERT [4 Certification Exam(s) ]
    PMI [15 Certification Exam(s) ]
    Polycom [2 Certification Exam(s) ]
    PostgreSQL-CE [1 Certification Exam(s) ]
    Prince2 [6 Certification Exam(s) ]
    PRMIA [1 Certification Exam(s) ]
    PsychCorp [1 Certification Exam(s) ]
    PTCB [2 Certification Exam(s) ]
    QAI [1 Certification Exam(s) ]
    QlikView [1 Certification Exam(s) ]
    Quality-Assurance [7 Certification Exam(s) ]
    RACC [1 Certification Exam(s) ]
    Real-Estate [1 Certification Exam(s) ]
    RedHat [8 Certification Exam(s) ]
    RES [5 Certification Exam(s) ]
    Riverbed [8 Certification Exam(s) ]
    RSA [15 Certification Exam(s) ]
    Sair [8 Certification Exam(s) ]
    Salesforce [5 Certification Exam(s) ]
    SANS [1 Certification Exam(s) ]
    SAP [98 Certification Exam(s) ]
    SASInstitute [15 Certification Exam(s) ]
    SAT [1 Certification Exam(s) ]
    SCO [10 Certification Exam(s) ]
    SCP [6 Certification Exam(s) ]
    SDI [3 Certification Exam(s) ]
    See-Beyond [1 Certification Exam(s) ]
    Siemens [1 Certification Exam(s) ]
    Snia [7 Certification Exam(s) ]
    SOA [15 Certification Exam(s) ]
    Social-Work-Board [4 Certification Exam(s) ]
    SpringSource [1 Certification Exam(s) ]
    SUN [63 Certification Exam(s) ]
    SUSE [1 Certification Exam(s) ]
    Sybase [17 Certification Exam(s) ]
    Symantec [134 Certification Exam(s) ]
    Teacher-Certification [4 Certification Exam(s) ]
    The-Open-Group [8 Certification Exam(s) ]
    TIA [3 Certification Exam(s) ]
    Tibco [18 Certification Exam(s) ]
    Trainers [3 Certification Exam(s) ]
    Trend [1 Certification Exam(s) ]
    TruSecure [1 Certification Exam(s) ]
    USMLE [1 Certification Exam(s) ]
    VCE [6 Certification Exam(s) ]
    Veeam [2 Certification Exam(s) ]
    Veritas [33 Certification Exam(s) ]
    Vmware [58 Certification Exam(s) ]
    Wonderlic [2 Certification Exam(s) ]
    Worldatwork [2 Certification Exam(s) ]
    XML-Master [3 Certification Exam(s) ]
    Zend [6 Certification Exam(s) ]





    References :


    Dropmark : http://killexams.dropmark.com/367904/11958654
    Dropmark-Text : http://killexams.dropmark.com/367904/12904135
    Blogspot : http://killexamsbraindump.blogspot.com/2017/12/get-high-marks-in-bcba-exam-with-these.html
    RSS Feed : http://feeds.feedburner.com/FreePass4sureBcbaQuestionBank
    Wordpress : https://wp.me/p7SJ6L-2ku
    Box.net : https://app.box.com/s/r3o1e2uy1gpnl7p20rgf3ljfdonce02r











    Killexams BCBA exams | Killexams BCBA cert | Pass4Sure BCBA questions | Pass4sure BCBA | pass-guaratee BCBA | best BCBA test preparation | best BCBA training guides | BCBA examcollection | killexams | killexams BCBA review | killexams BCBA legit | kill BCBA example | kill BCBA example journalism | kill exams BCBA reviews | kill exam ripoff report | review BCBA | review BCBA quizlet | review BCBA login | review BCBA archives | review BCBA sheet | legitimate BCBA | legit BCBA | legitimacy BCBA | legitimation BCBA | legit BCBA check | legitimate BCBA program | legitimize BCBA | legitimate BCBA business | legitimate BCBA definition | legit BCBA site | legit online banking | legit BCBA website | legitimacy BCBA definition | >pass 4 sure | pass for sure | p4s | pass4sure certification | pass4sure exam | IT certification | IT Exam | BCBA material provider | pass4sure login | pass4sure BCBA exams | pass4sure BCBA reviews | pass4sure aws | pass4sure BCBA security | pass4sure coupon | pass4sure BCBA dumps | pass4sure cissp | pass4sure BCBA braindumps | pass4sure BCBA test | pass4sure BCBA torrent | pass4sure BCBA download | pass4surekey | pass4sure cap | pass4sure free | examsoft | examsoft login | exams | exams free | examsolutions | exams4pilots | examsoft download | exams questions | examslocal | exams practice |



    International Edition Textbooks

    Save huge amounts of cash when you buy international edition textbooks from TEXTBOOKw.com. An international edition is a textbook that has been published outside of the US and can be drastically cheaper than the US edition.

    ** International edition textbooks save students an average of 50% over the prices offered at their college bookstores.

    Highlights > Recent Additions
    Showing Page 1 of 5
    Operations & Process Management: Principles & Practice for Strategic ImpactOperations & Process Management: Principles & Practice for Strategic Impact
    By Nigel Slack, Alistair Jones
    Publisher : Pearson (Feb 2018)
    ISBN10 : 129217613X
    ISBN13 : 9781292176130
    Our ISBN10 : 129217613X
    Our ISBN13 : 9781292176130
    Subject : Business & Economics
    Price : $75.00
    Computer Security: Principles and PracticeComputer Security: Principles and Practice
    By William Stallings, Lawrie Brown
    Publisher : Pearson (Aug 2017)
    ISBN10 : 0134794109
    ISBN13 : 9780134794105
    Our ISBN10 : 1292220619
    Our ISBN13 : 9781292220611
    Subject : Computer Science & Technology
    Price : $65.00
    Urban EconomicsUrban Economics
    By Arthur O’Sullivan
    Publisher : McGraw-Hill (Jan 2018)
    ISBN10 : 126046542X
    ISBN13 : 9781260465426
    Our ISBN10 : 1260084493
    Our ISBN13 : 9781260084498
    Subject : Business & Economics
    Price : $39.00
    Urban EconomicsUrban Economics
    By Arthur O’Sullivan
    Publisher : McGraw-Hill (Jan 2018)
    ISBN10 : 0078021782
    ISBN13 : 9780078021787
    Our ISBN10 : 1260084493
    Our ISBN13 : 9781260084498
    Subject : Business & Economics
    Price : $65.00
    Understanding BusinessUnderstanding Business
    By William G Nickels, James McHugh, Susan McHugh
    Publisher : McGraw-Hill (Feb 2018)
    ISBN10 : 126021110X
    ISBN13 : 9781260211108
    Our ISBN10 : 126009233X
    Our ISBN13 : 9781260092332
    Subject : Business & Economics
    Price : $75.00
    Understanding BusinessUnderstanding Business
    By William Nickels, James McHugh, Susan McHugh
    Publisher : McGraw-Hill (May 2018)
    ISBN10 : 1260682137
    ISBN13 : 9781260682137
    Our ISBN10 : 126009233X
    Our ISBN13 : 9781260092332
    Subject : Business & Economics
    Price : $80.00
    Understanding BusinessUnderstanding Business
    By William Nickels, James McHugh, Susan McHugh
    Publisher : McGraw-Hill (Jan 2018)
    ISBN10 : 1260277143
    ISBN13 : 9781260277142
    Our ISBN10 : 126009233X
    Our ISBN13 : 9781260092332
    Subject : Business & Economics
    Price : $77.00
    Understanding BusinessUnderstanding Business
    By William Nickels, James McHugh, Susan McHugh
    Publisher : McGraw-Hill (Jan 2018)
    ISBN10 : 1259929434
    ISBN13 : 9781259929434
    Our ISBN10 : 126009233X
    Our ISBN13 : 9781260092332
    Subject : Business & Economics
    Price : $76.00
    BCBABCBA
    By Peter W. Cardon
    Publisher : McGraw-Hill (Jan 2017)
    ISBN10 : 1260128474
    ISBN13 : 9781260128475
    Our ISBN10 : 1259921883
    Our ISBN13 : 9781259921889
    Subject : Business & Economics, Communication & Media
    Price : $39.00
    BCBABCBA
    By Peter Cardon
    Publisher : McGraw-Hill (Feb 2017)
    ISBN10 : 1260147150
    ISBN13 : 9781260147155
    Our ISBN10 : 1259921883
    Our ISBN13 : 9781259921889
    Subject : Business & Economics, Communication & Media
    Price : $64.00
    Result Page : 1 2 3 4 5